Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1998-05-06
2000-10-17
Shah, Mukund J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
544250, 544251, C07D49514, C07D49314, A61K 314985
Patent
active
061332755
ABSTRACT:
Compounds having the formula are .alpha..sub.1 adrenoreceptor antagonists. Processes for making these compounds, synthetic intermediates employed in these processes and a method for inhibiting .alpha..sub.1 adrenoreceptors and treating benign prostatic hyperplasia (also called benign prostatic hypertrophy or BPH) and other urological diseases such as BOO (bladder outlet obstruction), neurogenic bladder and gynecological syndromes such as dysmenorrhea are disclosed.
REFERENCES:
patent: 3719667 (1973-03-01), Gutowski
patent: 3840556 (1974-10-01), Kukolja
patent: 4670560 (1987-06-01), Press et al.
patent: 4835157 (1989-05-01), Press et al.
patent: 4939137 (1990-07-01), Russell et al.
patent: 5304560 (1994-04-01), Shimazaki et al.
patent: 5521181 (1996-05-01), Meyer et al.
patent: 5597823 (1997-01-01), Meyer et al.
patent: 5891882 (1999-04-01), Meyer et al.
Chapple, et al., British Journal Urology, vol., 63, pp. 487-496, 1989.
Janknegt, et al., European Urology, vol. 24, pp. 319-326, 1993.
Lepor, et al., Journal Urology, vol. 145, p. 263A, 1991.
Chow, et al., British Journal Urology, vol. 65, pp. 36-38, 1990.
Chapple, et al., Urology Int. vol. 45, pp. 47-55, 1990.
Andersson, Scandinavian Journal Urology and Nephrol., vol. 30, pp. 105-111, 1996.
Greengrass, et al., European Journal Pharmacology, vol. 55, pp. 323-326, 1979.
Hancock, et al., Journal Receptor Res., vol. 8, pp. 23-46, 1988.
Lee, C., et al., "Pharmacological characterization of LB50016, N-(4-amino)butyl 3-phenylpyrrolidine derivative, as a new 5-HT1A receptor agonist", Chemical Abstracts, Accession No. 131:74969 (1999).
Daanen Jerome F.
Ehrlich Paul P.
Meyer Michael D.
Ralston Jeffrey W.
Abbott Laboratories
Pope Lawrence S.
Rao Deepak R.
Shah Mukund J.
Ward Michael J.
LandOfFree
3-phenylpyrrolidine alpha-1 adrenergic compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 3-phenylpyrrolidine alpha-1 adrenergic compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 3-phenylpyrrolidine alpha-1 adrenergic compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-469220